Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

NCRI Presentation: Elements of epithelial cancer

NCRI

Published: 15 Dec 2009

Views: 13502

Rating:

Save

Prof Larry Norton - Memorial Sloan-Kettering Cancer Center, New York, USA

Could cancer cells not only spread away from a tumour but also return to it from other distant parts of the body? That’s the theory presented at the NCRI Cancer Conference by Dr Larry Norton of the Memorial Sloan-Kettering Cancer Center in New York, USA.

Related Videos

Trastuzumab deruxtecan effective against brain metastases in HER2-positive...

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival...

Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach...

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC ( Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach, Germany )

Addressing the rise of multiple myeloma in Rwanda

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Addressing the rise of multiple myeloma in Rwanda ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic...

Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia ( Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients...

Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy ( Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )

Adjuvant avelumab versus control does not significantly improve DFS but does...

Prof Pier Conte - University of Padova, Padova, Italy

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients ( Prof Pier Conte - University of Padova, Padova, Italy )

HER2DX assay and survival outcomes: An individual-patient level meta-analysis...

Dr Guillermo Villacampa - Vall d'Hebron Institute of Oncology (VHIO)...

HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC ( Dr Guillermo Villacampa - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

More from ecancer